Jennifer Cygan, Ph.D.

Chief Business Officer

Jennifer Cygan is the Chief Business Officer (interim) of EpiBiologics. Jen has over 25 years of business leadership experience in the biotechnology industry spanning company formation, corporate development, business development, program and portfolio management and alliance management. Jen is a Co-Founder and was previously the Chief Business Officer of Broadwing Bio, where she led business development, financing and program strategy activities. She was the interim Chief Business Officer of a number of innovative therapeutics platform companies including Eikon Therapeutics, GenEdit and Plexium, where she established partnerships with pharma and biotech partners and contributed to corporate and pipeline development. Previously, as one of Calico’s earliest employees, Jen built and led the program leadership team and managed Calico's $2.5B alliance with AbbVie. Jen spent 8 years in Business Development at Genentech where she led a team that sourced and established collaborations accessing novel therapeutic discovery technologies. Earlier in her career, Jen was a Director of Business Development at Genencor International and a Sr. Licensing Officer at the UCSF Office of Technology Management. Jen obtained her Ph.D. in Biology from Harvard University. She currently serves as a board member of Casma Therapeutics.